

Macroglobulinemia de Waldeströn

Bortezomibe e Rituximabe

Bortezomibe: 1,6 mg/m² IV semanalmente D1, D8, D15.

Rituximabe: 375 mg/m² IV semanalmente no ciclo 1 e 4.

a cada 28 dias no total de 6 ciclos

Ref. (01)

Bendamustina e Rituximabe

Rituximabe: 375 mg/m²/dia IV D1

Bendamustina: 90 mg/m²/dia IV durante 30 minutos D1 e D2

a cada 28 dias no total de 4 ciclos

Ref. (02)

1. Irene M. Ghobrial *et al.* Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia. *American Journal of Hematology.* 2010, 85: 670–674.
2. Mathias J. Rummel, Salah E. Al-Batran, Soo-Z. Kim, *et al.* Bendamustine Plus Rituximab Is Effective and Has a Favorable Toxicity Profile in the Treatment of Mantle Cell and Low-Grade Non-Hodgkin's Lymphoma *Journal of Clinical Oncology*, Vol 23, No 15, 2005: pp. 3383-3389.